Zhejiang Shengda Pharm (603079) — Net Asset Quality Index
Zhejiang Shengda Pharm (603079) has a Net Asset Quality Index of 74.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.19 Billion minus total liabilities of CN¥561.97 Million yields net assets of CN¥1.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Zhejiang Shengda Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Shengda Pharm Net Asset Quality Index Over Time (2012–2025)
This chart shows how Zhejiang Shengda Pharm's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 74.4%, representing net assets of CN¥1.63 Billion against total assets of CN¥2.19 Billion CNY. Explore Zhejiang Shengda Pharm operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Zhejiang Shengda Pharm (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Shengda Pharm from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 603079 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.4% | CN¥1.61 Billion | CN¥2.20 Billion | CN¥583.75 Million | ▲ +1.5 pp |
| 2024 | 71.9% | CN¥1.28 Billion | CN¥1.79 Billion | CN¥501.34 Million | ▼ -2.0 pp |
| 2023 | 73.9% | CN¥1.27 Billion | CN¥1.72 Billion | CN¥449.20 Million | ▼ -7.3 pp |
| 2022 | 81.2% | CN¥1.34 Billion | CN¥1.66 Billion | CN¥311.76 Million | ▲ +5.4 pp |
| 2021 | 75.8% | CN¥1.34 Billion | CN¥1.76 Billion | CN¥427.84 Million | ▼ -2.1 pp |
| 2020 | 77.9% | CN¥1.33 Billion | CN¥1.70 Billion | CN¥375.80 Million | ▲ +18.4 pp |
| 2019 | 59.5% | CN¥911.71 Million | CN¥1.53 Billion | CN¥620.88 Million | ▼ -6.6 pp |
| 2018 | 66.1% | CN¥828.42 Million | CN¥1.25 Billion | CN¥424.29 Million | ▼ -11.8 pp |
| 2017 | 78.0% | CN¥768.71 Million | CN¥985.98 Million | CN¥217.27 Million | ▲ +18.6 pp |
| 2016 | 59.4% | CN¥440.02 Million | CN¥741.37 Million | CN¥301.35 Million | ▼ -11.0 pp |
| 2015 | 70.4% | CN¥439.09 Million | CN¥624.13 Million | CN¥185.05 Million | ▲ +11.1 pp |
| 2014 | 59.3% | CN¥324.87 Million | CN¥548.27 Million | CN¥223.40 Million | ▲ +3.6 pp |
| 2013 | 55.7% | CN¥281.09 Million | CN¥505.09 Million | CN¥224.00 Million | ▲ +19.0 pp |
| 2012 | 36.7% | CN¥185.99 Million | CN¥507.42 Million | CN¥321.43 Million | — |